ArticleEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2026
Differential effects of semaglutide and colchicine on atrial remodeling in rats with reduced ejection fraction after myocardial infarction.
Article in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Colchicine initiated before radiofrequency-induced injury attenuates left atrial inflammation, fibrosis, and susceptibility to atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Article
- Colchicine in atrial fibrillation: mechanisms, highlights, and current evidence.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
aimsAtrial fibrillation (AF) is strongly associated with adverse outcomes, particularly in patients with heart failure (HF). AF susceptibility is driven by atrial remodelling, including electrical disarray, inflammation, and fibrosis, yet current therapies do not adequately target the underlying substrate. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, and colchicine, a broad-spectrum anti-inflammatory agent, have demonstrated cardiovascular benefits, but their effects on atrial remodelling remain unclear. We evaluated the effects of both drugs on atrial remodelling in post-myocardial infarction (MI) rats with reduced ejection fraction. METHODS AND
resultsMale rats underwent MI together with implantation of a chronic atrial pacing and recording system. One-week post-MI, animals with left ventricular ejection fraction ≤40% were randomized to semaglutide (40 µg/kg subcutaneously every 72 h), colchicine (100 µg/kg intraperitoneally daily), or vehicle for 21 days. Serial electrophysiological testing, echocardiography, histology, and molecular analyses were performed to characterize the AF substrate. Both semaglutide and colchicine reduced AF inducibility and AF duration, whereas semaglutide additionally reduced atrial signal complexity. Semaglutide attenuated atrial fibrosis, suppressed NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome expression, prevented connexin-43 (Cx43) lateralization, and reduced expression of the proarrhythmic small-conductance calcium-activated potassium channel 4 (SK4). Colchicine reduced NLRP3 and SK4 expression and inhibited p38, c-Jun N-terminal kinase (JNK), and protein kinase B (AKT) signalling, but did not prevent fibrosis or Cx43 remodelling.
conclusionIn the post-MI HF setting, both drugs demonstrated anti-arrhythmic and anti-remodelling effects. Their differential actions suggest that multiple pathways can be targeted to limit AF substrate progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.